Overview of Voir

What is Voir? (Tenoxicam Overview)

Property	Description
Active ingredient	Tenoxicam
Forms	Tablets, Lyophilized powder for injection
Pharmacological Class	Nonsteroidal Anti-inflammatory Drug (NSAID)
General Purpose	Relief of pain, inflammation, and fever
Origin	Synthetic Compound

What Type of Medicine is Voir?

Voir is a prescription-only medicinal product whose sole active component is the substance Tenoxicam. It is formally classified as a Nonsteroidal Anti-inflammatory Drug (NSAID), belonging specifically to the oxicam derivative subgroup. This compound is clinically recognized for its distinctive long-acting profile, a feature that differentiates it from many other agents in the NSAID class. Tenoxicam is a chemically synthetic compound derived from the thienothiazine structure and is used as a single-ingredient product.

Composition and Available Preparations of Voir

The composition of Voir relies entirely on the activity of Tenoxicam. This medicine is available in two distinct pharmaceutical preparations to suit various clinical needs: an oral dosage form (tablets) for systemic absorption, and a lyophilized powder for injection. The latter requires reconstitution with an aqueous sterile solvent to enable a parenteral route of administration (via injection). This dual-form availability is a key feature, allowing flexibility in systemic drug delivery when oral administration is not feasible.

Voir's General Purpose and Action

The general purpose of Voir is to provide effective symptomatic relief by reducing the interconnected signs of pain, inflammation, and fever. This is achieved because Tenoxicam acts as a cyclooxygenase (COX) inhibitor, blocking the production of prostaglandins, which are the key chemical messengers for pain and inflammation in the body. Consequently, the drug delivers a triple benefit: an anti-inflammatory effect, an analgesic effect (pain relief), and an antipyretic effect (fever reduction), offering broad control over these systemic symptoms.

What side effects are possible with Voir?

Possible side effects and safety information

Voir (Tenoxicam) is associated with a safety profile typical of the Nonsteroidal Anti-inflammatory Drug (NSAID) class, with adverse reactions formally categorized by frequency and the body system affected, according to regulatory documents.

Classification	Examples of Documented Reactions
Common	Digestive issues (dyspepsia, nausea, diarrhea, abdominal pain), headache, dizziness.
Uncommon	Vomiting, constipation, fatigue, somnolence, and observed changes in kidney or liver lab tests.

Serious Adverse Reactions

Official regulatory labeling highlights the potential for serious, sometimes fatal, events that may occur without warning. These include an increased risk of cardiovascular thrombotic events (such as myocardial infarction or stroke) and severe gastrointestinal complications (bleeding, ulceration, or perforation). Serious skin reactions (e.g., Stevens-Johnson Syndrome) are also documented. The risk of these serious events may occur early in treatment and may increase with the duration of use.

Population and Safety Limitations

The frequency and severity of adverse effects are generally higher in older adults, particularly concerning gastrointestinal risks. Safety-related restrictions prohibit the use of Voir in individuals with conditions such as severe heart failure, severe renal or hepatic impairment, or active gastrointestinal bleeding. These limitations reflect the necessity of avoiding use when pre-existing conditions significantly increase the risk of serious label-documented complications.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Voir (Tenoxicam) indicates that cases of overdose have not been specifically reported, meaning there is no formally documented acute symptom profile for overexposure in the product labeling.

However, as a Nonsteroidal Anti-inflammatory Drug (NSAID), severe, potentially fatal consequences are recognized as associated risks that could be exacerbated by high-dose exposure. These critical risks include gastrointestinal (GI) complications such as severe bleeding, ulceration, and perforation. Additionally, serious cardiovascular thrombotic events, including myocardial infarction and stroke, are acknowledged as severe systemic outcomes for this drug class.

In the event of a suspected overdosage, the mandated emergency action is to contact your regional poison control centre immediately for specialized guidance on exposure management. Urgent medical attention is required for any signs of these severe or potentially life-threatening complications.

Management for overdosage is officially described as supportive and symptomatic therapy. The labeling explicitly states that no specific antidote is known for Tenoxicam toxicity. Regulatory warnings further note that elderly patients carry an increased risk of serious adverse consequences, which is a key consideration in managing suspected overexposure given the potential for GI and cardiovascular risks.

Therapeutic Uses of Voir

What Voir Treats: Main Uses and Benefits

Voir (Tenoxicam) is primarily used to provide supportive symptomatic relief for conditions involving significant pain and inflammation, addressing symptoms related to inflammatory or irritative states. It is generally used across conditions presenting with acute or recurrent episodes.

The therapeutic scope may include long-term support for chronic inflammatory joint diseases such as Rheumatoid Arthritis and Osteoarthritis, as well as short-term assistance for acute episodes like Acute Gouty Arthritis. It is also applied in managing inflammation from soft tissue injuries (sprains, strains), tendonitis, and acute discomfort, including severe Primary Dysmenorrhea.

A key benefit involves managing symptoms that interfere with daily functioning. It provides supportive relief when symptoms interfere with routine activities, assisting with maintaining functional stability during difficult episodes. This use may help patients cope more steadily with symptom fluctuations, contributing to easing the overall symptom load.

Quick Fact: Supportive Relief for Inflammation and Joint Stiffness

Regulatory References

Health Canada Product Monograph

Eligibility and Restrictions for Use

Eligibility Scope

Voir (Tenoxicam) eligibility is determined by strict adherence to official regulatory contraindications and restrictions, primarily for adults. Use in children and adolescents under 18 years of age is not recommended as safety and efficacy are not established in this population.

Contraindicated Populations (Must Not Use)

Voir is absolutely contraindicated in patients with a history of severe heart failure, severe hepatic or renal impairment, or a known hypersensitivity to the drug or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

Other absolute non-eligibility includes:

Patients with active peptic ulceration or active gastrointestinal bleeding.
Individuals who have experienced asthma, rhinitis, or urticaria following use of NSAIDs or aspirin.
Women in the third trimester of pregnancy (after 20 or 30 weeks, per specific regulatory guidance).

Condition-Specific and Conditional Use

Use requires caution and close monitoring in certain populations due to an increased risk profile. These include older adults, and patients with pre-existing conditions such as mild-to-moderate renal or hepatic impairment, or a history of hypertension and mild-to-moderate congestive heart failure.

Pregnancy and Lactation Eligibility

The medicine is contraindicated in the third trimester of pregnancy. Use during the first and second trimesters and while breastfeeding is not recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Voir (Tenoxicam) documents specific interaction patterns that alter drug exposure or increase organ toxicity risks. Co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and COX-2 selective inhibitors is restricted due to a formally documented risk of severe gastrointestinal events.

High-Level Interaction Patterns:

Increased Hemorrhage Risk: Co-administration with Oral Anticoagulants, Antiplatelet Agents, Oral Corticosteroids, or SSRIs/SNRIs results in an officially stated increased risk of bleeding or gastrointestinal ulceration.
Organ Toxicity/Efficacy: Combinations with Diuretics, ACE Inhibitors, ARBs, Ciclosporin, or Tacrolimus are documented to increase the risk of renal failure and may attenuate the intended effect of antihypertensive agents.
Exposure Alteration: Voir may increase the plasma concentration of Lithium and reduce the renal clearance of Methotrexate.
Timing Rules: The official label documents a mandatory separation rule: administration must be spaced for 8 to 12 days following the use of Mifepristone.

Population and Substance Notes:

Caution is required for Elderly Patients due to higher risk from concomitant therapy. While food delays the rate of absorption, the total exposure is unchanged. Use with substantial quantities of Ethanol may increase the risk of liver-related problems.

Mechanism of Action

Core Mechanism: Non-Selective Enzyme Inhibition

Voir acts by reversibly blocking the activity of the Cyclooxygenase (COX) enzymes, targeting both the constitutive COX-1 and the inducible COX-2 isoforms. This intervention suppresses the entire synthesis of prostaglandins, which are key lipid mediators in multiple physiological pathways, initiating a cascade that dampens excessive physiological responses.

Modulating Inflammatory and Nociceptive Signaling

The resulting reduction in prostaglandin levels directly limits the two key physiological consequences of inflammation: vasodilation and peripheral nociceptor sensitization. By eliminating these chemical triggers, the mechanism modulates local tissue responses and reduces the transmission of pain signals from the site of distress, contributing to adjustments in local reactivity.

Central Control and Physiological Trade-offs

Additionally, the drug engages a central mechanism by blocking prostaglandin synthesis within the hypothalamus. This action helps restore the body's core temperature set point, allowing the activation of physiological heat-dissipating mechanisms that normalize the systemic state. However, the non-selective inhibition simultaneously restricts COX-1 activity required for homeostatic functions, such as maintaining the protective barrier of the gastric mucosa and regulating renal blood flow under certain conditions.

Dosage and Administration Information

How to Use Voir

Voir (Tenoxicam) is administered based on the core principle of using the lowest effective dose for the shortest duration necessary to achieve therapeutic effect.

Administration and Dosage Patterns

The medicine is available as oral tablets and as a lyophilized powder for injection (20 mg vial), allowing for flexibility in systemic drug delivery. The approved routes are oral, intramuscular (IM), and intravenous (IV).

Usage Scenario	Dosing Regimen (Adults)	Frequency and Duration
General Maintenance	20 mg	Once daily, administered at the same time each day.
Acute Gout Attack	40 mg for 2 days, followed by 20 mg	Once daily for a total of 7 days.
Long-Term Chronic Use	10 mg	Once daily; the maximum daily dose for chronic disorders is 20 mg.

Procedural and Contextual Instructions

For oral administration, tablets must be swallowed whole with water and taken preferably with or immediately after meals to mitigate the risk of irritation, which is a key condition for proper intake.

The injectable powder requires reconstitution with 2 mL of sterile water for injections and must be used immediately. Parenteral administration (IM or IV) is specified as a bolus injection; infusion is restricted due to the potential for precipitation.

Population-Specific Use

Special caution and the use of the lowest possible dose are required in older adults. For patients with severe renal impairment (creatinine clearance less than 25 mL/min), there is insufficient data to recommend administration, and the drug is generally avoided. No dosing recommendations have been established for the pediatric population.

Recent Clinical Evidence

Research evidence / Overview of Studies for Voir (Tenoxicam)

Evidence for Chronic Inflammatory and Degenerative Joint Conditions

Research exploring Voir (Tenoxicam) has been conducted in conditions that are characterized by fluctuating symptoms and functional limitations, particularly chronic joint diseases. Studies monitored the use of Voir in conditions presenting with cycles of stability and flare-ups, such as Rheumatoid Arthritis (RA) and Osteoarthritis (OA).

For both RA and OA, research examined how symptoms evolved in the observed populations during the study period. Studies were conducted during periods of increased symptom activity and focused on outcomes related to physical discomfort, such as pain intensity and the duration of morning stiffness. These evaluations were primarily short-term to intermediate-term Randomized Controlled Trials (RCTs). These short-term trials reported measurements of pain and stiffness that were documented for Voir and for the other treatment groups studied.

Research on Acute Pain and Soft Tissue Inflammation

Research has also focused on conditions involving periods of heightened symptoms that require short-term intervention. Voir was evaluated in studies focusing on acute gouty arthritis, where research examined outcomes describing episodic or acute changes in symptoms such as pain intensity and joint tenderness. Similarly, Voir was observed in studies related to Extra-Articular / Soft Tissue Rheumatism (e.g., sprains, strains).

For Post-operative Pain, Voir was evaluated in its injectable form as part of research exploring temporary physiological imbalance following surgery. Data show patterns related to how Voir, when used as an adjunct to a comprehensive pain regimen, was associated with changes in both pain scores and opioid use in the observed populations.

Areas of Research Uncertainty and Study Gaps

Most of the evidence for Voir related to efficacy is derived from trials with limited follow-up durations, typically ranging from a few weeks to a few months. Controlled data focused on long-term safety and efficacy are not fully established. The results of the clinical trials conducted mainly apply only to the adult populations studied, and data for certain groups remain insufficient. For instance, subgroup findings are uncertain when looking at groups defined by specific comorbidities or extreme disease severity levels. The research primarily focuses on symptomatic measures, meaning there is limited clinical data on any effect the medicine may have on the underlying progression of chronic diseases.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Voir (FAQ)

Q: What specific condition is Voir officially approved to treat?

According to regulatory documents, Voir is approved for the relief of pain and inflammation associated with muscle and joint disorders. This includes conditions such as rheumatoid arthritis, osteoarthritis, backache, and other musculoskeletal issues like sprains and strains. Official product information describes its function as controlling these symptoms.

Q: How quickly can a person generally expect to notice the effects of Voir?

Official information indicates that Voir is a long-acting medicine, a characteristic supported by its long half-life, which enables once-daily use. While the exact time it takes to notice the effects is not detailed in patient information, regulatory information notes its long half-life, which is associated with sustained presence in the body over time.

Q: How long does Voir stay in the body after the last use?

Voir has a long elimination half-life (the time it takes for half the drug to be removed) that typically ranges from 59 to 74 hours. Due to this long profile, the active ingredient can remain in the body for several days after the final use.

Q: What should generally be done if a person uses more Voir than described?

Regulatory safety data instructs that if someone uses more of this medicine than described, or accidentally swallows it, immediate professional guidance must be sought from a Poison Center or a doctor. The label may advise rinsing the mouth before seeking help.

Q: What is the function of the inactive ingredients in the Voir pill?

Regulatory documents list the inactive ingredients (known as excipients) in the pill formulation. These substances are necessary to help form the tablet, maintain the medicine's stability, and control how the drug is released and delivered in the body.

Q: What does the term "Black Box Warning" mean, if it applies to Voir?

The term refers to a Boxed Warning, which is a special type of caution that the FDA requires to be placed prominently on a drug's label. This is done to call attention to serious risks associated with the medicine.

Q: Is there information about Voir's effects on fertility?

Official regulatory documents indicate that taking Voir may make it more difficult to get pregnant. Consultation with a healthcare professional is described in the official guidance for individuals planning a pregnancy or having difficulty conceiving.

Q: Do the official prescribing documents mention any mental health concerns?

The official prescribing documents list central nervous system (CNS) side effects. These documented CNS side effects include confusion and rare instances of hallucinations (seeing or hearing things that are not there).

Q: What are the implications if a dose of Voir is missed?

Official guidance indicates that if a dose is missed and it is almost time for the next scheduled dose, the missed dose is skipped. Otherwise, the dose is taken as soon as it is remembered. Official guidance states that two doses must never be taken at the same time to make up for a missed one.

Q: Are there specific food products or supplements that interact with Voir?

Official guidance recommends informing a healthcare professional about all treatments, including any vitamins or herbal products. This is due to the potential for interactions that a professional can assess and provide appropriate guidance for.

Q: Is Voir a treatment that must be used long-term?

The official safety documentation highlights that the long-term use of medicines in this class may be associated with an increased risk of cardiovascular events (such as heart attack or stroke). Regulatory documents describe using the medicine for the shortest time and at the lowest effective dose possible, with duration of use subject to professional monitoring.

Q: What is meant by a "contraindication" for Voir?

A contraindication is a strict regulatory term indicating a specific condition or circumstance where the medicine is officially not recommended for use. Examples include active peptic ulcers, a severe allergy to the drug, or certain stages of pregnancy, as use in these cases could lead to serious documented harm.

Q: Does Voir affect a person's ability to drive or operate machinery?

Official documentation lists side effects that affect the central nervous system, such as dizziness, confusion, and changes to eyesight. These effects could potentially impair a person’s alertness and coordination, and official documentation indicates caution may be necessary when operating a vehicle or machinery.

Q: Are there specific laboratory tests required before or during the use of Voir?

Regulatory documents indicate that for patients with existing kidney, liver, or heart problems, professional monitoring and check-ups of these organ functions are warranted. This is part of standard monitoring for the safe use of this class of medicine.

Q: Are there any specific lifestyle changes mentioned in connection with Voir?

Anti-inflammatory medicines are documented to increase the risk of certain kidney problems, especially in individuals who are dehydrated. Official warnings about kidney risk, particularly in dehydrated individuals, suggest that maintaining adequate hydration is relevant while using this medicine.

Q: How does the body process or break down Voir?

According to pharmacokinetic data, Voir is primarily broken down (metabolized) in the liver into inactive substances. It is then mostly removed from the body through a combination of the urine and feces.

How should Voir be stored and disposed of?

How to Store and Dispose of Voir (Tenoxicam)

Official regulatory guidelines stipulate specific conditions to maintain the stability of Voir (Tenoxicam).

Storage Requirement	Condition
Temperature	Store at or below 25, C (controlled room temperature).
Protection	Must be protected from light and moisture and must not be frozen.
Packaging	Keep the medicine in its original container and the outer carton, and keep containers tightly closed.
Child Safety	Keep out of the sight and reach of children.

For the lyophilized powder, the reconstituted solution should be used immediately, or within the defined in-use stability period (e.g., 24 hours). Unused or expired Voir must be disposed of according to local regulations. Medicine should not be thrown into household waste or flushed into wastewater systems.

Voir